ArticleEuropean radiology2025
The Avocado Sign: A novel imaging marker for nodal staging in rectal cancer.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CT-based Node-RADS for metastatic lymph node detection in colon cancer and influence of microsatellite instability.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the diagnostic performance of the Avocado Sign, a novel contrast-enhancement-based MR imaging marker, for prognostication of mesorectal lymph node spread in rectal cancer.
methodsThis retrospective study included 106 patients with rectal cancer who underwent MRI examination. The Avocado Sign, defined as a hypointense core within an otherwise homogeneously hyperintense lymph node on contrast-enhanced T1-weighted images, was assessed. Of the cohort, 77 patients received neoadjuvant chemoradiotherapy followed by restaging MRI. Histopathological examination served as the reference standard. Diagnostic metrics were calculated and compared between subgroups using chi-square tests. Interobserver agreement was evaluated using Cohen's kappa.
resultsThe Avocado Sign demonstrated high diagnostic accuracy for predicting lymph node involvement, with an overall sensitivity of 88.7%, specificity of 84.9%, PPV of 85.5%, NPV of 88.2%, and accuracy of 86.8%. The area under the ROC curve was 0.87. Subgroup analysis revealed excellent performance in both patients undergoing surgery alone (sensitivity 100%, specificity 83.3%) and those receiving neoadjuvant therapy (sensitivity 84.2%, specificity 85.4%). Interobserver agreement was almost perfect (κ = 0.92).
conclusionThe Avocado Sign is a promising imaging predictor for mesorectal lymph node status in rectal cancer. Its straightforward application, high reproducibility, and remarkable diagnostic accuracy underline its potential to refine MRI staging. However, further validation in larger, prospective multicenter studies is warranted to confirm these findings and assess their impact on clinical decision-making. KEY POINTS: Question Can the Avocado Sign on contrast-enhanced MRI improve mesorectal lymph node staging in rectal cancer independently of classical morphological criteria? Findings The Avocado Sign demonstrated high sensitivity (88.7%) and specificity (84.9%) as a standalone marker for predicting mesorectal lymph node involvement. Clinical relevance Incorporating contrast-enhanced sequences and the Avocado Sign into MRI protocols enhances nodal staging accuracy in rectal cancer, potentially informing treatment decisions. Further validation is required to confirm its effectiveness and compare it with existing criteria.
Indexed as
Identifiers
40009088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.